|
1
|
Wasley A and Alter MJ: Epidemiology of
hepatitis C: Geographic differences and temporal trends. Semin
Liver Dis. 20:1–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keck ZY, Li TK, Xia J, Bartosch B, Cosset
FL, Dubuisson J and Foung SK: Analysis of a highly flexible
conformational immunogenic domain a in hepatitis C virus E2. J
Virol. 79:13199–13208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jacobson IM, Gordon SC, Kowdley KV,
Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz
E, Everson G, Bennett M, et al POSITRON Study: FUSION Study:
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without
treatment options. N Engl J Med. 368:1867–1877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeuzem S, Dusheiko GM, Salupere R, Mangia
A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM,
Symonds WT, et al VALENCE Investigators: Sofosbuvir and ribavirin
in HCV genotypes 2 and 3. N Engl J Med. 370:1993–2001. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carrère-Kremer S, Montpellier C, Lorenzo
L, Brulin B, Cocquerel L, Belouzard S, Penin F and Dubuisson J:
Regulation of hepatitis C virus polyprotein processing by signal
peptidase involves structural determinants at the p7 sequence
junctions. J Biol Chem. 279:41384–41392. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lindenbach BD, Evans MJ, Syder AJ, Wölk B,
Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR,
McKeating JA and Rice CM: Complete replication of hepatitis C virus
in cell culture. Science. 309:623–626. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khan AG, Miller MT and Marcotrigiano J:
HCV glycoprotein structures: what to expect from the unexpected.
Curr Opin Virol. 12:53–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dorner M, Horwitz JA, Robbins JB, Barry
WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR,
et al: A genetically humanized mouse model for hepatitis C virus
infection. Nature. 474:208–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meredith LW, Wilson GK, Fletcher NF and
McKeating JA: Hepatitis C virus entry: beyond receptors. Rev Med
Virol. 22:182–193. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pileri P, Uematsu Y, Campagnoli S, Galli
G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G
and Abrignani S: Binding of hepatitis C virus to CD81. Science.
282:938–941. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartosch B, Dubuisson J and Cosset FL:
Infectious hepatitis C virus pseudo-particles containing functional
E1–E2 envelope protein complexes. J Exp Med. 197:633–642. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Molina S, Castet V, Pichard-Garcia L,
Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A,
Larrey D, et al: Serum-derived hepatitis C virus infection of
primary human hepatocytes is tetraspanin CD81 dependent. J Virol.
82:569–574. 2008. View Article : Google Scholar :
|
|
13
|
Meuleman P, Hesselgesser J, Paulson M,
Vanwolleghem T, Desombere I, Reiser H and Leroux-Roels G: Anti-CD81
antibodies can prevent a hepatitis C virus infection in vivo.
Hepatology. 48:1761–1768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lavie M, Sarrazin S, Montserret R,
Descamps V, Baumert TF, Duverlie G, Séron K, Penin F and Dubuisson
J: Identification of conserved residues in hepatitis C virus
envelope glycoprotein E2 that modulate virus dependence on CD81 and
SRB1 entry factors. J Virol. 88:10584–10597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keck ZY, Angus AG, Wang W, Lau P, Wang Y,
Gatherer D, Patel AH and Foung SK: Non-random escape pathways from
a broadly neutralizing human monoclonal antibody map to a highly
conserved region on the hepatitis C virus E2 glycoprotein
encompassing amino acids 412–423. PLoS Pathog. 10:e10042972014.
View Article : Google Scholar
|
|
16
|
Qin ZL, Ju HP, Gao TT, Wang WB, Ren H,
Zhao P and Qi ZT: Two conserved histidines (His490 and His621) on
the E2 glycoprotein of hepatitis C virus are critical for
CD81-mediated cell entry. J Gen Virol. 96:1389–1399. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Albecka A, Montserret R, Krey T, Tarr AW,
Diesis E, Ball JK, Descamps V, Duverlie G, Rey F, Penin F and
Dubuisson J: Identification of new functional regions in hepatitis
C virus envelope glycoprotein E2. J Virol. 85:1777–1792. 2011.
View Article : Google Scholar :
|
|
18
|
Krepstakies M, Lucifora J, Nagel CH,
Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T,
Baumert TF, Brand-enburg K, et al: A new class of synthetic peptide
inhibitors blocks attachment and entry of human pathogenic viruses.
J Infect Dis. 205:1654–1664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu S, McCormick KD, Zhao W, Zhao T, Fan D
and Wang T: Human apolipoprotein E peptides inhibit hepatitis C
virus entry by blocking virus binding. Hepatology. 56:484–491.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bukong TN, Kodys K and Szabo G: A novel
human radixin peptide inhibits hepatitis C virus infection at the
level of cell entry. Int J Pept Res Ther. 20:269–276. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lü X, Yao M, Zhang JM, Yang J, Lei YF,
Huang XJ, Jia ZS, Ma L, Lan HY, Xu ZK and Yin W: Identification of
peptides that bind hepatitis C virus envelope protein E2 and
inhibit viral cellular entry from a phage-display peptide library.
Int J Mol Med. 33:1312–1318. 2014.PubMed/NCBI
|
|
22
|
Wakita T, Pietschmann T, Kato T, Date T,
Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami
M, et al: Production of infectious hepatitis C virus in tissue
culture from a cloned viral genome. Nat Med. 11:791–796. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhong J, Gastaminza P, Cheng G, Kapadia S,
Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T and Chisari
FV: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci
USA. 102:9294–9299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blanco-Canosa JB and Dawson PE: An
efficient Fmoc-SPPS approach for the generation of thioester
peptide precursors for use in native chemical ligation. Angew Chem
Int Ed Engl. 47:6851–6855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alsaleh K, Delavalle PY, Pillez A,
Duverlie G, Descamps V, Rouillé Y, Dubuisson J and Wychowski C:
Identification of basic amino acids at the N-terminal end of the
core protein that are crucial for hepatitis C virus infectivity. J
Virol. 84:12515–12528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krieger SE, Zeisel MB, Davis C, Thumann C,
Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, et
al: Inhibition of hepatitis C virus infection by anti-claudin-1
antibodies is mediated by neutralization of E2-CD81-claudin-1
associations. Hepatology. 51:1144–1157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Owsianka AM, Timms JM, Tarr AW, Brown RJ,
Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH
and Ball JK: Identification of conserved residues in the E2
envelope glycoprotein of the hepatitis C virus that are critical
for CD81 binding. J Virol. 80:8695–8704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Drummer HE, Boo I, Maerz AL and
Poumbourios P: A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif
in hepatitis C virus glycoprotein E2 is a determinant of CD81
binding and viral entry. J Virol. 80:7844–7853. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang J, Randall G, Higginbottom A, Monk
P, Rice CM and McKeating JA: CD81 is required for hepatitis C virus
glycoprotein-mediated viral infection. J Virol. 78:1448–1455. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ji C, Liu Y, Pamulapati C, Bohini S,
Fertig G, Schraeml M, Rubas W, Brandt M, Ries S, Ma H and Klumpp K:
Prevention of hepatitis C virus infection and spread in human liver
chimeric mice by an anti-CD81 monoclonal antibody. Hepatology.
61:1136–1144. 2015. View Article : Google Scholar
|
|
31
|
Mekky RY, El-Ekiaby NM, Hamza MT, Elemam
NM, El-Sayed M, Esmat G and Abdelaziz AI: Mir-194 is a hepatocyte
gate keeper hindering HCV entry through targeting CD81 receptor. J
Infect. 70:78–87. 2015. View Article : Google Scholar
|
|
32
|
Zhang YY, Zhang BH, Ishii K and Liang TJ:
Novel function of CD81 in controlling hepatitis C virus
replication. J Virol. 84:3396–3407. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cartier F, Marcq I, Douam F, Ossart C,
Regnier A, Debuysscher V, Lavillette D and Bouhlal H: The
expression of the hepatocyte SLAMF3 (CD229) receptor enhances the
hepatitis C virus infection. PLoS One. 9:e996012014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Al Olaby RR, Cocquerel L, Zemla A, Saas L,
Dubuisson J, Vielmetter J, Marcotrigiano J, Khan AG, Vences Catalan
F, Perryman AL, et al: Identification of a novel drug lead that
inhibits HCV infection and cell-to-cell transmission by targeting
the HCV E2 glycoprotein. PLoS One. 9:e1113332014. View Article : Google Scholar : PubMed/NCBI
|
